Variable | Comorbidity-only model | Drug-extended model | |||
---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | ||
Comorbidity profile | Congestive heart failure treated (EI group 1) | 1.53*** | [1.46;1.60] | 1.50*** | [1.43;1.58] |
Congestive heart failure untreated (EI group 1) | 1.58** | [1.42;1.76] | 1.53*** | [1.39;1.68] | |
Cardiac arrhythmia treated (EI group 2) | 1.03n.s. | [0.98;1.08] | Not selected | ||
Cardiac arrhythmia untreated (EI group 2) | Not selected | 1.02ns | [0.95;1.08] | ||
Valvular disease treated (EI group 3) | 0.93* | [0.88;0.99] | 0.95 | [0.89;1.00] | |
Valvular disease untreated (EI group 3) | 1.10* | [1.01;1.21] | 1.13**. | [1.03;1.24] | |
Pulmonary hypertension treated | 1.40*** | [1.31;1.56] | 1.22*** | [1.13;1.31] | |
Pulmonary hypertension untreated | 1.43*** | [1.31;1.56] | 1.55*** | [1.42;1.70] | |
Peripheral vascular disorders treated (EI group 5) | 1.11*** | [1.05;1.18] | 1.12*** | [1.05;1.18] | |
Peripheral vascular disorders untreated (EI group 5) | 1.13*** | [1.07;1.20] | 1.13*** | [1.07;1.20] | |
Hypertension without complications treated (EI group 6) | 0.80** | [0.73;0.88] | Not selected | ||
Hypertension without complications untreated (EI group 6) | Not selected | 1.00 | [0.94;1.05] | ||
Hypertension with complications treated (EI group 7) | 0.86*** | [0.82;0.90] | 0.89** | [0.83;0.95] | |
Hypertension with complications untreated (EI group 7) | 1.01ns | [0.88;1.16] | 0.86*** | [0.75;0.97] | |
COPD treated (EI group 10) | 0.91*** | [0.86;0.95] | 0.98ns | [0.94;1.03] | |
COPD untreated (EI group 10) | 0.97ns. | [0.92;1.01] | Not selected | ||
Diabetes without complications treated (EI group 11) | 1.09* | [1.02;1.17] | Not selected | ||
Diabetes without complications untreated (EI group 11) | 1.16** | [1.10;1.22] | 0.99ns | [0.60;1.62] | |
Diabetes with complications treated (EI group 12) | 1.12*** | [1.06;1.20] | 1.03ns | [0.63;1.59] | |
Diabetes with complications untreated (EI group 12) | 1.20*** | [1.12;1.30] | 1.19*** | [1.11;1.28] | |
Hypothyroidism (EI group 13) | 0.89*** | [0.84;0.95] | 0.90*** | [0.85;0.95] | |
Renal failure (EI group 14) | 1.27*** | [1.21;1.33] | 1.26*** | [1.20;1.32] | |
Liver disease (EI group 15) | 1.05ns. | [1.00;1.11] | 1.04ns | [0.99;1.10] | |
Metastatic carcinoma (EI group 19) | 2.51*** | [2.35;2.67] | 2.51*** | [2.36;2.68] | |
Solid tumour without metastasis (EI group 20) | 1.15*** | [1.10;1.21] | 1.15*** | [1.10;1.21] | |
Rheumatoid Arthritis/Connective Tissue Disorder (EI group 21) | 0.89*** | [0.84;0.95] | 0.88*** | [0.83;0.94] | |
Coagulopathy (EI group 22) | 1.40*** | [1.32;1.49] | 1.43*** | [1.35;1.52] | |
Obesity (EI group 23) | 0.87*** | [0.83;0.92 | 0.90*** | [0.83;0.94] | |
Weight loss (EI group 24) | 1.56*** | [1.46;1.66] | 1.53*** | [1.44;1.63] | |
Fluid and electrolyte disorders (EI group 25) | 1.74** | [1.67;1.82] | 1.70*** | [1.63;1.78] | |
Deficiency anaemia (EI group 27) | 1.11** | [1.04;1.19] | 1.10** | [1.03;1.18] | |
Depression treated (EI group 31) | 1.07ns | [1.00;1.15] | 1.00ns | [0.95;1.06] | |
Depression untreated (EI group 31) | 0.99ns. | [0.93;1.04] | Not selected | ||
IHD treated | 0.97ns | [0.93;1.01] | Not selected | ||
IHD untreated | 1.33*** | [1.24;1.42] | 1.04*** | [0.98;1.09] | |
GERD treated | 0.92** | [0.87;0.98] | 0.89*** | [0.83;0.95] | |
GERD untreated | 0.92*. | [0.84;0.99] | 0.95ns | [0.87;1.03] | |
OSAS | 0.76*** | [0.70;0.82] | 0.77*** | [0.71;0.84] | |
Lung cancer | 1.86*** | [1.74;1.98] | 1.80*** | [1.69;1.92] | |
Medication intake | Digitalis glycosides | 1.07ns | [0.99;1.16] | ||
Anti-arrhythmic drugs | 0.86* | [0.75;0.98] | |||
Diuretic drugs | 1.24*** | [1.18;1.31] | |||
Statins | 0.85*** | [0.80;0.90] | |||
Beta-blockers | 0.92*** | [0.88;0.97] | |||
ACE inhibitors | 0.83*** | [0.79;0.87] | |||
Angiotensin-I-antagonists | 0.73*** | [0.68;0.78] | |||
Antiplatelet drugs | 1.08* | [1.02;1.15] | |||
Heparin (−derivates) | 0.84*** | [0.98;1.11] | |||
Vitamin-K antagonists | 1.04ns | [0.78;0.90] | |||
Proton pump inhibitors | 1.05* | [1.00;1.09] | |||
H2-antagonists | 1.24** | [1.07;1.43] | |||
Treatment with anti-depressants | 1.12*** | [1.05;1.18 | |||
Treatment with anti-diabetic drugs | 1.07ns | [0.66;1.75] | |||
Long-acting beta2 agonists (LABA) | 0.98ns | [0.91;1.05] | |||
Long-acting muscarinic antagonists (LAMA) | 1.05ns | [1.00;1.11] | |||
Inhaled corticosteroids (ICS) | 0.89** | [0.82;0.97] | |||
Combination product LABA/ICS | not selected | ||||
Combination product LABA/LAMA | not selected | ||||
Specific PH drugs | 1.85*** | [1.56;2.18] |